Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Substantial reduction in losses
EPS at Rs 32.19
Anti-malaria API facility will be operational in 15-18 months
Income declines marginally
Subscribe To Our Newsletter & Stay Updated
